Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Lenalidomide (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
- Indications B cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2018 Planned End Date changed from 1 Jan 2023 to 20 Jan 2023.
- 22 Feb 2018 Planned primary completion date changed from 1 May 2018 to 20 May 2018.
- 25 Jan 2017 Planned End Date changed from 1 Nov 2020 to 1 Jan 2023.